Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma Protocol Version 5.0 (2010-01-27)

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-004272-20

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the therapeutic activity and safety of E7389 at a dose of 1.4mg/m(2) on days 1 and 8 every 3 weeks in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies.


Critère d'inclusion

  • Advanced and/or metastatic soft tissue sarcoma